Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase
- PMID: 2960778
- DOI: 10.1007/BF01253600
Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase
Abstract
The effects of a COMT-inhibitor, U-0521, and a MAO-B-inhibitor, 1-deprenyl, on L-dopa-induced circling behaviour were compared in 6-OHDA-lesioned rats. The actions of U-0521 and 1-deprenyl on the anti-cataleptic effect of L-dopa were also studied. Both U-0521 and 1-deprenyl were found to potentiate L-dopa-induced circling behaviour and anti-cataleptic effect of L-dopa. In both test systems the L-dopa potentiation of 1-deprenyl was longer-lasting than that caused by U-0521. Thus inhibition of COMT, like inhibition of MAO, is able to enhance the central effects of L-dopa. This principle might be beneficial in the treatment of Parkinson's disease especially if COMT-inhibitors with greater performance can be developed.
Similar articles
-
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.Pharmacology. 2003 Jun;68(2):81-8. doi: 10.1159/000069533. Pharmacology. 2003. PMID: 12711835
-
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.Mov Disord. 1997 Jul;12(4):497-505. doi: 10.1002/mds.870120404. Mov Disord. 1997. PMID: 9251066 Clinical Trial.
-
Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.J Neural Transm (Vienna). 1997;104(6-7):593-603. doi: 10.1007/BF01291878. J Neural Transm (Vienna). 1997. PMID: 9444560
-
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.J Neural Transm Suppl. 1986;22:91-105. J Neural Transm Suppl. 1986. PMID: 3097263 Review.
-
The pharmacology of Parkinson's disease: basic aspects and recent advances.Experientia. 1984 Nov 15;40(11):1165-72. doi: 10.1007/BF01946641. Experientia. 1984. PMID: 6437857 Review.
Cited by
-
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review.
-
The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson's Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On.Neurol Ther. 2024 Aug;13(4):1039-1054. doi: 10.1007/s40120-024-00629-2. Epub 2024 May 29. Neurol Ther. 2024. PMID: 38809484 Free PMC article. Review.
-
Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.J Neural Transm Gen Sect. 1995;102(1):19-34. doi: 10.1007/BF01276562. J Neural Transm Gen Sect. 1995. PMID: 8785021
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous